89Zr-trastuzumab-PET gauges treatment response in gastric cancer

04/24/2013 | HealthImaging.com

PET imaging with 89Zr-trastuzumab is effective in monitoring treatment response in animals with human epidermal growth factor receptor 2-positive stomach cancer being treated with afatinib, according to findings from a study published in The Journal of Nuclear Medicine. Researchers said 89Zr-trastuzumab-PET performed better than 18F-FDG-PET in determining drug uptake. There is a need for human studies to validate the efficacy of the method in monitoring treatment response, researchers added.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC